Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.
Background: There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.
Methods: TURKMI study, as a nation-wide registry, will be conducted in 50 percutaneous coronary intervention -capable centres selected from each EuroStat NUTS region in Turkey according to their population sampling weight, prioritizing the volume of hospital in each region. All consecutive patients with acute MI admitted to the coronary care units within the 48 hours of symptom onset will be prospectively enrolled during a predefined 2-week period.
The first step of the study has cross-sectional design in which baseline information such as symptoms, risk factors, time periods at each step from symptom onset to revascularization, way of arrival to hospital, biochemical analysis and in-hospital management and outcome will be assessed. The second step has a cohort characteristics in which enrolled patients will be followed-up up to 2 years. Follow-up visits will be conducted at 1st, 6th, 12th and 24th months, and predictors and risk of cardiovascular events, and implementation of guidelines will be assessed as secondary outcomes.
Conclusion: The national TURKMI registry is expected to provide important information to improve the national policy of the diagnosis, management and outcomes of MI in Turkey
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| no intervention | Other | no intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants died | all cause of death including cardiovascular death | from enrollment till to 2 years follow up |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants developed cardiovascular morbidity | non-fatal MI, stroke, coronary or peripheral revascularization, emergency department visit due to chest pain or dyspnea, hospitalization for heart failure will be assessed at 1st month and then at every 6 month intervals until the second year. | from enrollment till to 2 years follow up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Patients unwilling or unable to consent will be excluded.
Not provided
Not provided
Not provided
Not provided
The screened population will consist of all consecutive patients presenting with suspected acute MI in the participating hospitals. Men and women aged ≥18 years will be enrolled if they fulfil the following inclusion criteria;
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| MERAL KAYIKCIOGLU, Prof | Contact | +905324123489 | meral.kayikcioglu@gmail.com | |
| MUSTAFA K EROL, Prof | Contact | erolmk@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| MUSTAFA K EROL, prof | Istanbul Private Sisli International Kolan Hospital, | Study Director |
| MERAL KAYIKCIOGLU, prof | Ege University School of Medicine Department of Cardiology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Meral Kayikcioglu | Recruiting | Izmir | 35100 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| MUSTAFa KILICKAP, prof | ANKARA University School of Medicine Department of Cardiology | Principal Investigator |